简介 Everything you need to make the most of your Heart Failure 2024 experience in Lisbon. Access the programme, the list of speakers, the floorplan, and the list of exhibitors whenever you need them.新内容 版本记录 版本1.0.6 Amélioration des performances App 隐私 查看详情 开发者“ESC ...
2023年ESC更新发布的《急性和慢性心衰诊断和治疗指南》首次写入非奈利酮,推荐T2DM和CKD患者使用非奈利酮以降低心衰住院或心血管死亡的风险(Ⅰ,A)[3]。近几年非奈利酮的临床试验日渐丰富(表2),其中FIDELIO-DKD和FIGARO-DKD研究及其相关...
今年,在阿姆斯特丹举行的欧洲心脏病学会(ESC)大会举办了9场热线会议,讨论了心血管药物治疗领域一些最受期待且可能改变实践的临床试验。 Heart failure (HF) was the focus of the congress, accounting for nearly a third of the ...
ESC心力衰竭 ISSN:2055-5822 是否OA:No ESSN:2055-5822 国际简称:ESC HEART FAIL 3区中科院分区 3.407影响因子 2024年SCI期刊影响因子出炉获取相关优质资源精准匹配期刊 SCI优质选题 严选服务 安全可靠 四区 质量保证 保密协议 化学工程/制药,医学 了解详情...
ESC Heart Failure由The Heart Failure Association of the European Society of Cardiology出版,是一本医学-心脏病学和心血管医学刊。JCR分区为Q2,中科院分区为医学2区。根据分区水平来看,投稿难度中等。 ISSN:2055-5822 ESC Heart Failure于2014年创刊,主编是Magnus Bäck。其CiteScore为5.2,与其他著名期刊如JAMA ...
Since the publication of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure (HF),1there have been several randomized controlled trials that should change patient management ahead of the next scheduled full guidelines. This 2023 Focused Update addresses changes ...
《Esc Heart Failure》(《ESC心力衰竭》)是一本由The Heart Failure Association of the European Society of Cardiology出版的Medicine-Cardiology and Cardiovascular Medicine学术刊物,主要刊载Medicine-Cardiology and Cardiovascular Medicine相关领域研究成果与实践,旨在打造一种学术水平高、可读性强、具有全球影响力的学术...
Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis Presenter: Pardeep S. Jhund September 01, 2024 Presentation ESC 2024 Edoxaban-Based Long-Term Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Disease: The EPIC-CAD Randomized Clinical...
期刊简称ESC HEART FAIL 参考译名《欧洲心脏病学会:心力衰竭》 核心类别 SCIE(2024版), 目次收录(知网),外文期刊, IF影响因子 自引率 主要研究方向医学-CARDIAC & CARDIOVASCULAR SYSTEMS心脏和心血管系统 ESC Heart Failure《欧洲心脏病学会:心力衰竭》(双月刊). ESC Heart Failure is the open access journal ...
Congestive heart failure, Hypertension, Age, Diabetes, Stroke or TIA-Vascular disease 充血性心力衰竭、高血压、年龄、糖尿病、中风或TIA血管疾病 Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition ...